Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades Aprea Therapeutics to Underweight

JP Morgan analyst Jessica Fye downgrades Aprea Therapeutics (NASDAQ:APRE) from Neutral to Underweight.
byBenzinga Newsdesk
August 20, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Jessica Fye downgrades Aprea Therapeutics (NASDAQ:APRE) from Neutral to Underweight.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0